These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17443037)

  • 1. Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C.
    Tahara H; Kojima A; Hirokawa T; Oyama T; Naganuma A; Maruta S; Okada K; Ban S; Yoshida K; Takagi H; Mori M
    Intern Med; 2007; 46(8):473-6. PubMed ID: 17443037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis.
    Solans R; Bosch JA; Esteban I; Vilardell M
    Clin Exp Rheumatol; 2004; 22(5):625-8. PubMed ID: 15485018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sudden onset of diabetic ketoacidosis during consensus interferon therapy for chronic viral hepatitis C.
    Nylen ES; Marathe IC; Khan IA; Azevedo R; Hirsch KR
    Am J Med Sci; 2008 Apr; 335(4):329-30. PubMed ID: 18414077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis-like disease secondary to alpha interferon.
    Matsuo T; Takabatake R
    Ocul Immunol Inflamm; 2002 Dec; 10(4):299-304. PubMed ID: 12854039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferon system activation and association with disease manifestations in systemic sclerosis.
    Eloranta ML; Franck-Larsson K; Lövgren T; Kalamajski S; Rönnblom A; Rubin K; Alm GV; Rönnblom L
    Ann Rheum Dis; 2010 Jul; 69(7):1396-402. PubMed ID: 20472592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.
    Mazziotti G; Sorvillo F; Stornaiuolo G; Rotondi M; Morisco F; Ruberto M; Cioffi M; Amato G; Caporaso N; Gaeta GB; Carella C
    J Endocrinol Invest; 2002; 25(7):624-30. PubMed ID: 12150338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C.
    Kawazoe T; Araki M; Lin Y; Ogawa M; Okamoto T; Yamamura T; Wakakura M; Murata M
    Intern Med; 2012; 51(18):2625-9. PubMed ID: 22989839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Yurci A; Guven K; Torun E; Gursoy S; Baskol M; Akgun H; Ozbakir O; Yucesoy M
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):811-5. PubMed ID: 17700270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.
    Kim D; Peck A; Santer D; Patole P; Schwartz SM; Molitor JA; Arnett FC; Elkon KB
    Arthritis Rheum; 2008 Jul; 58(7):2163-73. PubMed ID: 18576347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy.
    Hadem J; Cornberg M; Hauptmann C; Süttmann U; Manns MP; Wedemeyer H
    Z Gastroenterol; 2008 Sep; 46(9):880-2. PubMed ID: 18810674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1).
    Hass HG; Klein R; Nehls O; Kaiser S
    J Clin Gastroenterol; 2009; 43(5):470-6. PubMed ID: 19247202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1.
    Dimitroulopoulos D; Dourakis SP; Xinopoulos D; Tsamakidis K; Paraskevas E
    J Viral Hepat; 2004 Sep; 11(5):477-8. PubMed ID: 15357656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I interferon dysregulation in Systemic Sclerosis.
    Skaug B; Assassi S
    Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis.
    Airo' P; Scarsi M; Rossi M; Mondini M
    Rheumatol Int; 2008 May; 28(7):703-7. PubMed ID: 18066551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Consensus and peg-interferon in chronic hepatitis C. Therapy for refractory cases?].
    Kaiser S
    MMW Fortschr Med; 2001 Apr; 143(16):36-7. PubMed ID: 11367991
    [No Abstract]   [Full Text] [Related]  

  • 16. Exacerbation of Graves ophthalmopathy with interferon-alpha therapy.
    DeMartelaere SL; Green MK; Shore JW
    Ophthalmic Plast Reconstr Surg; 2007; 23(4):319-21. PubMed ID: 17667110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.
    Papaioannides D; Fotinou M; Korantzopoulos P; Latsi P; Sinapidis D; Akritidis N; Orphanidou D
    Med Sci Monit; 2004 Jan; 10(1):CS5-7. PubMed ID: 14704637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy.
    Sasso FC; Carbonara O; Di Micco P; Coppola L; Torella R; Niglio A
    Br J Clin Pharmacol; 2003 Aug; 56(2):238-9. PubMed ID: 12895200
    [No Abstract]   [Full Text] [Related]  

  • 19. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.
    Conlon KC; Urba WJ; Smith JW; Steis RG; Longo DL; Clark JW
    Cancer; 1990 May; 65(10):2237-42. PubMed ID: 2346907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
    Malaguarnera M; Pistone G; Neri S; Romano M; Brogna A; Musumeci S
    BioDrugs; 2004; 18(6):407-13. PubMed ID: 15571424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.